Allergy Therapeutics (AGY) Shares Traded Flat Despite Trial News

The Allergy Therapeutics plc (LON: AGY) share price was trading flat for the day despite the company announcing that it had completed dosing healthy volunteers within the first two cohorts of its Phase I PROTECT trial. The trial is testing the firm’s novel virus-like particle (VLP)-based peanut allergy vaccine candidate. 

The company noted that the external safety review committee (SRC) had approved the dosing of the successive cohorts.  Furthermore, the SRC approved the beginning of subcutaneous dose escalation in peanut-allergic subjects following the completion of the skin-prick testing phase in April 2023.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

The subcutaneous dose escalation in peanut-allergic participants marks the beginning of the early proof of concept phase of the PROTECT trial. The company expects to begin this critical stage of the PROTECT trial soon. The trial’s full results are expected in 2024. 

The trial is being conducted in peanut-allergic patients and healthy volunteers and is split into two parts. Part A is an open-label study of four groups (cohorts) of healthy participants (Group A1) who will be dosed subcutaneously in ascending dose concentrations of VLP peanut.  

The second group (Group A2) of peanut-allergic patients had undergone skin prick tests conducted with rising concentrations of the vaccine candidate (completed in April 2023). 

Part B is a double-blind, placebo-controlled trial enrolling peanut-allergic patients who will receive rising doses of the vaccine candidate injected subcutaneously. The PROTECT trial builds on the findings from the VLP001 study conducted at the Imperial College London.

Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: “We welcome the positive progress in our PROTECT trial and are pleased with the safety review committee’s approval to begin multiple subcutaneous dosing of peanut-allergic patients in the final phase of the trial.”

“Peanut allergy is one of the most common types of food allergies. For some people, even the smallest amounts of peanuts can cause a potentially life-threatening reaction. A safe and effective short-course vaccine that provides long-term protection and a long-lasting protective immune response can bring a paradigm shift in treating peanut allergy, changing the lives of those living with the allergy.”

Allergy Therapeutics (AGY) share price. 

The Allergy Therapeutics (AGY) share price was trading flat for the day despite today’s announcement.